Study #2022-1079
A phase I/IIa, open-label, multi-center study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the DNA polymerase theta inhibitor ART6043 administered orally as monotherapy and in combination to patients with advanced or metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
ART6043, Olaparib, Niraparib
Description
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Metastatic Solid Tumor
Study phase:
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.